Table 2—

Effects of placebo or simvastatin on lipids, endothelium, and endocrine parameters in hypercholesterolemic patients

Placebo
Simvastatin
ANOVA
10 mg
20 mg
40 mg
80 mg
BaselineTreatmentBaselineTreatmentBaselineTreatmentBaselineTreatmentBaselineTreatment
n3230323131
Age (years)59 ± 257 ± 258 ± 260 ± 259 ± 20.676
Sex (male/female)15/1714/1615/1714/1715/16
BMI (kg/m2)25.7 ± 0.625.5 ± 0.625.9 ± 0.726.0 ± 0.727.0 ± 0.526.8 ± 0.526.8 ± 0.626.8 ± 0.626.4 ± 0.526.3 ± 0.50.444
Lipids (mg/dl)
Total cholesterol267 ± 6247 ± 6246 ± 3179 ± 5256 ± 7191 ± 6264 ± 6166 ± 5253 ± 6155 ± 6<0.001
Triglycerides146 ± 15159 ± 18131 ± 12124 ± 8147 ± 18124 ± 16*149 ± 16135 ± 13151 ± 11119 ± 70.149
LDL cholesterol179 ± 6162 ± 6162 ± 399 ± 4174 ± 7109 ± 6181 ± 788 ± 5170 ± 579 ± 5<0.001
ApoB134 ± 4129 ± 4125 ± 393 ± 3131 ± 391 ± 3139 ± 489 ± 4129 ± 574 ± 4<0.001
HDL cholesterol57 ± 254 ± 254 ± 152 ± 252 ± 249 ± 254 ± 248 ± 253 ± 253 ± 30.316
ApoA-I161 ± 3164 ± 4160 ± 4170 ± 4160 ± 4161 ± 4164 ± 4168 ± 5161 ± 5163 ± 40.514
Vasomotor
FMD dilation(%)4.69 ± 0.224.91 ± 0.164.82 ± 0.267.70 ± 0.295.00 ± 0.216.78 ± 0.164.78 ± 0.266.74 ± 0.324.92 ± 0.307.53 ± 0.41<0.001
NTG dilation(%)14.14 ± 0.6513.98 ± 0.5414.60 ± 0.6814.66 ± 0.6314.22 ± 0.5114.32 ± 0.6114.04 ± 0.6014.42 ± 0.7714.08 ± 0.7014.16 ± 0.690.976
Inflammation
hsCRP (mg/l)0.95 (0.46–2.10)0.90 (0.35–1.95)0.64 (0.27–2.91)0.43 (0.27–1.01)1.05 (0.40–2.35)0.90 (0.50–1.95)0.73 (0.44–1.39)0.59 (0.38–1.44)1.52 (0.89–4.82)0.89 (0.64–3.05)0.363
Insulin resistance
ADP (μg/ml)6.6 ± 1.06.6 ± 0.96.4 ± 1.05.9 ± 0.9*6.0 ± 1.05.3 ± 1.0*6.2 ± 0.85.7 ± 0.7*6.4 ± 0.85.7 ± 0.7*0.011
Insulin (μU/ml)3.31 ± 0.453.04 ± 0.333.02 ± 0.493.59 ± 0.432.95 ± 0.445.01 ± 0.702.98 ± 0.314.27 ± 0.483.14 ± 0.313.56 ± 0.320.006
Glucose (mg/dl)95 ± 489 ± 389 ± 987 ± 886 ± 384 ± 391 ± 491 ± 591 ± 298 ± 4*0.501
QUICKI0.43 ± 0.010.44 ± 0.010.46 ± 0.020.43 ± 0.01*0.46 ± 0.020.41 ± 0.010.44 ± 0.020.41 ± 0.01*0.44 ± 0.020.41 ± 0.01*0.034
  • Data are expressed as means ± SEM or median (range). There were no significant differences among baseline values.

  • *

    * P < 0.05;

  • P < 0.01;

  • P < 0.001 for comparison with each baseline value;

  • P < 0.05 for comparison with the value after therapy with placebo.

  • QUICKI = 1/[log (insulin) + log (glucose)] (20). ADP, adiponectin; Apo, apolipoprotein; hsCRP, high-sensitivity CRP; NTG, nitroglycerin.